VeinWay
Advanced Vein Blockage Crossing Tools
Startup A Health Tech & Life Sciences Est. 2020
Total Raised
$7.43M
A
Last Round
$5M
4 rounds
Investors
2
2 public
Team
2
1-10 employees
Confidence
99/100
News
8
articles
Patents
1
About
VeinWay is focused on developing a novel technology for crossing chronically occluded veins. VeinWay's Traversa delivers the first dedicated device designed for venous recanalization that will improve outcomes and allow physicians to reliably, safely and easily complete endovascular procedures in a timely manner for the effective treatment of CVOs. The Traversa is an enabling technology which will disrupt the market by democratizing physician access to the treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or that are currently in development. All other solutions are either off-label tools that have a high risk of perforation, or standard crossing tools with no specific indication or features for venous recanalization. Physicians use them as workarounds when the procedure fails with standard guidewires. In contrast, Traversa is the first tool designed specifically for crossing CVOs, allowing for an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time. VeinWay was created as part of the entrepreneur in residence program with the MEDX Xelerator, which supports and helps inventors and entrepreneurs cultivate early-stage ideas addressing complex unmet clinical needs.
Classification
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target Customer
Healthcare & Life SciencesHealthcareProviders
Business Model
B2B
Tags
medical-devicescardiologyvasculartreatmentsmedical-technologiescardiovascular
Funding & Events
Sep 2023
Seed $1.6M
Consensus Business Group (CBG), Boston Scientific
Nov 2023
A Round $5M
May 2021
Non-equity $800K
MEDX Xelerator, Consensus Business Group (CBG), Israel Innovation Authority
Dec 2020
Non-equity $35K
Israel Innovation Authority
News (8)
May 28, 2024 · venousnews.com
growth-positive
VeinWay CEO: “This is a pivotal year for us” - Venous News
InvestmentExpand
Sep 7, 2023 · www.medxelerator.com
Growth-Positive
VeinWay Closes Oversubscribed SAFE Round and Begins Series A Round
InvestmentManagement Changes
May 23, 2023 · www.calcalistech.com
growth-positive
VeinWay opens up the path to stop blood clots in underappreciated patients | CTech
Investment
Mar 1, 2022 · medium.com
growth-positive
Health Tech: Jordan Pollack on How VeinWay's Technology Can Make an Important Impact on Our Overall...
Management ChangesExpand
Nov 23, 2021 · www.medxelerator.com
growth-positive
MEDX Xelerator Invests In Three New Health Technology Ventures
PartnersInvestment
Feb 19, 2021 · www.jpost.com
growth-positive
https://www.jpost.com/israel-news/from-minnesota-to-tel-aviv-oleh-finds-israelis-welcoming-and-warm-659386
Investment
Dec 3, 2020 · www.cathlabdigest.com
MEDX Xelerator Approves New "X Lab" Project to Improve Treatment of Peripheral Venous Disease Care, Forms VeinWay Under CEO Jordan Pollack
Dec 3, 2020 · www.medxelerator.com
growth-positive
MEDX Xelerator Approves New "X Lab" Project to Improve Treatment of Peripheral Venous Disease Care, Forms VeinWay Under CEO Jordan Pollack
Investment
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
6
District
Center District
Founded
2020
Registrar
516276490
Crunchbase
veinway
Locations
Ariel Sharon Boulevard 8, Or Yehuda, Israel
Links
Website
LinkedIn
Admin
Last Update
Sep 7, 2024
Claimed
Yes
Missing
markets
Team (2)
Jordan Pollack
Co-founder & CEO
Founder
Ben Friesem
Co-founder & CTO
Founder
Internal
Created by
Yotam Maman (yotamm1988@gmail.com)
Created
2021-02-21T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)